Lilly's next-gen drug shows greater weight loss than Zepbound in late-stage trial

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Eli Lilly's stock drops as it slashes the price of Zepbound: Time to buy the dip?

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...
Mercury News

Zepbound trims more belly fat than Wegovy, study shows

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines. Zepbound won on ...
CNN

A pharmacy benefit manager stopped covering a GLP-1 for obesity. Now there’s a lawsuit

A class-action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly’s blockbuster GLP-1 drug to treat obesity. When the major pharmacy benefit manager ...